Tag Archives: STTR

Proposal Development Support – SBIR/STTR

Posted on by
Reply

The Center for Biotechnology is offering one-on-one SBIR/STTR proposal development counseling and iterative grant writing services to companies – application for next cohort is June 5th!

Companies that have completed our intensive 2-day workshop (or similar program) and/or have previously submitted an unsuccessful SBIR/STTR proposal in the past are eligible to apply. Services provided under this program are awarded through a competitive application process and include a weekly “best practices” proposal development webinar followed by iterative review of section drafts to guide stepwise development of the proposal from start to finish.

Companies selected for this follow-on counseling will be required to contribute $250 and will receive up to 10 hours of iterative proposal development services valued at $2000. These services will be subsidized by the Center for Biotechnology through the Downstate New York SBIR Assistance Program.
Interested companies should apply online no later than June 5, 2020. The application can be found here: https://forms.gle/5m9kAN8nUnzEyXyi9.

Contact Kate Hutchinson kate.hutchinson@stonybrook.edu with questions.

Free Course from NIH: Entrepreneurial Finance for Biomedical Innovators

Posted on by
Reply

The course is presented in a series of five sequential videos. The video modules and course details can be found here: https://www.nibib.nih.gov/entrepreneurial-finance-course

The National Institutes of Health (NIH) supports the development and commercialization of biomedical technologies through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. With the goal of bringing life-saving innovations to market, NIH SBIR/STTR funding provides early-stage seed capital to US-owned small businesses. While the commercialization of biomedical technologies can require a significant amount of both time and money, rigorous financial planning can help navigate and mitigate risks for small businesses and can enhance chances of success along the pathway to market. For biomedical innovators considering funding through the NIH SBIR/STTR programs (https://sbir.nih.gov), it is imperative to evaluate the use of federal grant funding within the context of a broader financial plan.

Course Objectives
The purpose of this course is to present biomedical entrepreneurs with a detailed framework for building a step-wise, validated financial plan. Moving beyond the short-term perspective of immediate financing needs to a comprehensive, long-term financial plan will increase the probability of success for your venture. The primary learning objectives for this course are as follows:

– Understand the importance of financial planning for your small business
– Gain perspective on SBIR/STTR funding within the broader context of your financial plan
– Learn practical approaches to developing a long-term financial plan
– Evaluate the various sources of funding
– Examine the use of comparables in validating your financial plan

 

Important SBIR/STTR Information Update from NIH

Posted on by
Reply

Update courtesy of BBC Entrepreneurial Training and Consulting

NIH is strongly encouraging small businesses to contact the appropriate Institute or Center early in their application planning to ensure their technology is a priority for the Institute/Center.

An updated SBIR/STTR Application Guide with additional instructions for SBIR Direct Phase II application preparation and submission will be posted by November 26, 2018. The following sections of each FOA are changed:

Part 2, Section I. Funding Opportunity Description The following has been added at the end of the section for each FOA:

PA-18-573 The following Components will not accept an SBIR Direct-to-Phase II submission:
– National Institute of Nursing Research (NINR)
– National Center for Complementary and Integrative Health (NCCIH)

PA-18-574 The following Components will not accept an SBIR Direct-to-Phase II submission:
– National Institute of Environmental Health Sciences (NIEHS )
– National Institute of Nursing Research (NINR)
– National Center for Complementary and Integrative Health (NCCIH)
– Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP)
– Centers for Disease Control and Prevention (CDC) (All Components of CDC)
– U.S. Food and Drug Administration (FDA) (All Components of FDA)

Part 2, Section II. Award Information for both PA-18-573 and PA-18-574. Application types now allowed are:
– New (Phase I, Fast-Track)
– New (Direct Phase II)
– Renewal (Phase II)
– Resubmission (all phases)
– Phase IIB Competing Renewal (Phase IIB)
– Revision

The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types.

Chronus Pharmaceuticals Receives Phase I STTR

Posted on by
Reply

Chronus Pharmaceuticals has announced that it has received a $299,172 Phase I Small Business Technology Transfer (STTR) award in partnership with the Department of Chemistry at Stony Brook University.

Funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) will be used to establish feasibility of an antibody diagnostic for detecting childhood tuberculosis. The research will be lead by LIBH Researcher Nicole S. Sampson, PhD in the Department of Chemistry, who will serve as principle investigator on the award and work in close collaboration with Chronus Pharmaceuticals.

CFB Director Testifies Before Joint Congressional Hearing

Posted on by
Reply

On Thursday May 4, 2017 Center for Biotechnology Director Dr. Clinton Rubin was fortunate to testify at a joint congressional hearing on “Improving the Small Business Innovation Research and Small Business Technology Transfer Programs”. Dr. Rubin was present to discuss the NIH-REACH Program – which is the program that supported the creation of the Long Island Bioscience Hub.

Dr. Rubin spoke about the importance of initiatives like REACH which promote the development of “Phase 0” proof-of concept centers embedded within university communities. The activities of these centers are critical in promoting under-realized innovations out of academic labs and into the hands of patients as Universities often face significant challenges when it comes to commercializing translational research. He talk about the fact that in a very short amount of time, the three hubs created by the REACH program have already seen major impacts at our institution, fostering new intellectual property, increasing credibility with the investor community, promoting a shift in the academic culture, attracting new licensing opportunities, and most importantly, catalyzing the formation of new companies – some of which have successfully secured SBIR funding.

Programs like REACH fuel the growth of the small business community around university centers, and drives science towards successful new treatments for disease.

The committee hearing is available to view at this link. Dr. Rubin’s comments begin at 2:53:06

CFB Director Clint Rubin and Director of Operations Diane Fabel at a joint congressional hearing on May 4, 2017.